These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23686863)

  • 21. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
    Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
    Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of long term testosterone replacement therapy on bone mineral density.
    Fillo J; Levcikova M; Luha J; Ondrus D
    Bratisl Lek Listy; 2019; 120(4):291-294. PubMed ID: 31023052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of testosterone replacement on trabecular architecture in hypogonadal men.
    Benito M; Vasilic B; Wehrli FW; Bunker B; Wald M; Gomberg B; Wright AC; Zemel B; Cucchiara A; Snyder PJ
    J Bone Miner Res; 2005 Oct; 20(10):1785-91. PubMed ID: 16160736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
    Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
    Emmelot-Vonk MH; Verhaar HJ; Nakhai Pour HR; Aleman A; Lock TM; Bosch JL; Grobbee DE; van der Schouw YT
    JAMA; 2008 Jan; 299(1):39-52. PubMed ID: 18167405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The "Aging Males' Symptoms" Scale (AMS): predictive value for lowered circulating androgens.
    Zengerling F; Schrader AJ; Cronauer MV; Stemann H; Schrader M; Rinnab L
    Aging Male; 2012 Dec; 15(4):253-7. PubMed ID: 23078021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment.
    Crawford BA; Liu PY; Kean MT; Bleasel JF; Handelsman DJ
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3167-76. PubMed ID: 12843161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The assessment of testosterone and radioisotopic index of bone metabolism and bone mineral density in men with testosterone deficiency after one year of testosterone therapy.
    Tryniszewski W; Kamiński G; Maziarz Z; Nowak M; Gadzicki M; Radek M
    Nucl Med Rev Cent East Eur; 2018; 21(1):14-19. PubMed ID: 29319133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex steroids, biochemical markers, bone mineral density and histomorphometry in male osteoporosis patients.
    Fassbender WJ; Balli M; Görtz B; Hinrichs B; Kaiser HE; Tracke HS
    In Vivo; 2000; 14(5):611-8. PubMed ID: 11125545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo precision of the GE lunar iDXA for the assessment of lumbar spine, total hip, femoral neck, and total body bone mineral density in severely obese patients.
    Carver TE; Christou NV; Court O; Lemke H; Andersen RE
    J Clin Densitom; 2014; 17(1):109-15. PubMed ID: 23896494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
    Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
    Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution.
    van den Bergh JP; Hermus AR; Spruyt AI; Sweep CG; Corstens FH; Smals AG
    Osteoporos Int; 2001; 12(1):55-62. PubMed ID: 11305084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens.
    Jankowski CM; Gozansky WS; Kittelson JM; Van Pelt RE; Schwartz RS; Kohrt WM
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4767-73. PubMed ID: 18812486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.